Table 1.
pN+ disease without presurgical chemotherapy
| Study (year) | Number of patients | % of RC-LND patients | Follow up | Survival | # of positive nodes predicting survival | Comments |
| Lerner (1993) | 132 | 22% | 5.5 yrs (2.6–18.8 yrs) | Median PFS 1.5 rys, 5 yr OS 29% | 6 | pT3b associated with increased risk of progression and death |
| Aprikian (1995) | 25 | 21.6% | 2.2 yrs (0.6–8.7 yrs) | Median OS 2.3 yrs, 3 yr OS 33% | – | |
| Vieweg (1999) | 193 | 25.3% | 7.7 yrs | Median OS ∼2 yrs, 5yr OS 31.2% | – | |
| Mills (2001) | 83 | 18% | – | Median OS 1.7 yrs, 5 yrs OS 29% | 5 | Lymph node capsule perforation and diameter >0.5 cm associated with increased mortality |
| Stein (2003) | 244 | 23% | >10 yrs (0–28 yrs) | 5 yrs RFS 35% | 8 | Extravesical primary tumor and 15 or less removed lymph nodes conferred higher recurrece |
| Frank (2003) | 154 | – | 4.5 yrs (0.1–13.9 yrs) | Median CSS 4.5 yrs, 5 yr CSS 39.4% | 5 | Adjuvant chemo and number of positive LN’s associated with CSS |
| Madersbacher (2003) | 124 | 24% | 3.8 yrs (0.1–14.7 yrs) | 5yr OS 26% | – | Adjuvant chemo improved OS |